Sponsor Overview
Explore verified public information about EMD Serono Research & Development Institute, Inc.'s expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 2 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Official Statements
Score contribution: 100 — 2 supporting sources.
“If a physician wants to request one of our experimental medicines for a patient with a serious or life-threatening disease or condition when there is no comparable or satisfactory alternative, the physician should send a request to earlyaccess@emdserono.com. Before doing so, the physician should review our Position Statement on Early Access to Experimental Medicine, download the PDF here, which outlines the principles and criteria we use to evaluate all early access requests. We will respond to requests within three business days.”
“Through our Early Access Program, we can, under specific circumstances, enable patients to gain early access to new, potentially life-saving products. The offer is aimed at people with serious conditions who have already received all available therapies without success. It allows them to be treated with products that have already been clinically tested but have not yet been approved. Furthermore, we offer patients who participated in one of our clinical studies post-study access to the investigational product, provided that certain conditions are met.”
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.